Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleGastrointestinal, Hepatic, Pulmonary, and Renal

Inhibiting Protein Arginine Deiminases Has Antioxidant Consequences

Erin E. Witalison, Xiangli Cui, Anne B. Hofseth, Venkataraman Subramanian, Corey P. Causey, Paul R. Thompson and Lorne J. Hofseth
Journal of Pharmacology and Experimental Therapeutics April 2015, 353 (1) 64-70; DOI: https://doi.org/10.1124/jpet.115.222745
Erin E. Witalison
Department of Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, South Carolina (E.E.W., X.C., A.B.H., L.J.H.); Shanxi Medical University, Taiyuan, Shanxi, China (X.C.); Department of Chemistry, The Scripps Research Institute, Scripps Florida, Jupiter, Florida (V.S.); Department of Chemistry, University of North Florida, Jacksonville, Florida (C.P.C.); and Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts (P.R.T.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiangli Cui
Department of Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, South Carolina (E.E.W., X.C., A.B.H., L.J.H.); Shanxi Medical University, Taiyuan, Shanxi, China (X.C.); Department of Chemistry, The Scripps Research Institute, Scripps Florida, Jupiter, Florida (V.S.); Department of Chemistry, University of North Florida, Jacksonville, Florida (C.P.C.); and Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts (P.R.T.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne B. Hofseth
Department of Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, South Carolina (E.E.W., X.C., A.B.H., L.J.H.); Shanxi Medical University, Taiyuan, Shanxi, China (X.C.); Department of Chemistry, The Scripps Research Institute, Scripps Florida, Jupiter, Florida (V.S.); Department of Chemistry, University of North Florida, Jacksonville, Florida (C.P.C.); and Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts (P.R.T.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Venkataraman Subramanian
Department of Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, South Carolina (E.E.W., X.C., A.B.H., L.J.H.); Shanxi Medical University, Taiyuan, Shanxi, China (X.C.); Department of Chemistry, The Scripps Research Institute, Scripps Florida, Jupiter, Florida (V.S.); Department of Chemistry, University of North Florida, Jacksonville, Florida (C.P.C.); and Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts (P.R.T.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Corey P. Causey
Department of Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, South Carolina (E.E.W., X.C., A.B.H., L.J.H.); Shanxi Medical University, Taiyuan, Shanxi, China (X.C.); Department of Chemistry, The Scripps Research Institute, Scripps Florida, Jupiter, Florida (V.S.); Department of Chemistry, University of North Florida, Jacksonville, Florida (C.P.C.); and Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts (P.R.T.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul R. Thompson
Department of Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, South Carolina (E.E.W., X.C., A.B.H., L.J.H.); Shanxi Medical University, Taiyuan, Shanxi, China (X.C.); Department of Chemistry, The Scripps Research Institute, Scripps Florida, Jupiter, Florida (V.S.); Department of Chemistry, University of North Florida, Jacksonville, Florida (C.P.C.); and Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts (P.R.T.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lorne J. Hofseth
Department of Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, South Carolina (E.E.W., X.C., A.B.H., L.J.H.); Shanxi Medical University, Taiyuan, Shanxi, China (X.C.); Department of Chemistry, The Scripps Research Institute, Scripps Florida, Jupiter, Florida (V.S.); Department of Chemistry, University of North Florida, Jacksonville, Florida (C.P.C.); and Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts (P.R.T.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Structure of the pan-PAD inhibitor, Cl-amidine.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    (A) Outline of the AOM/DSS mouse model of colitis used in this study. (B) Effects of Cl-amidine on the colon histology score in the acute AOM/DSS colitis model. Six mice from each group described in Materials and Methods were euthanized on day 14, and colons were measured and harvested. Then the histology score was determined. Weight was recorded every 48 hours during the 14-day experiment. Values represent the mean ± S.E. of the mean. Representative H&E-stained colons are shown for each group. *Significant difference from the AOM + DSS group (P < 0.01).

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    iNOS levels are reduced in the colons of mice treated with Cl-amidine. Six mice from each of the indicated groups were euthanized on day 14, and colons were harvested from each animal and stained with iNOS as described in Materials and Methods. (A) Immunoreactivity score (IRS) for each group. Values represent the mean ± S.E. *Significant difference from the AOM + DSS only group (P < 0.01). (B) Representative sections of indicated group. Positive staining is brown colored. (400× magnification.)

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Cl-amidine attenuates the activation of macrophages and protects from DNA damage in target epithelial cells in vitro. (A) iNOS and Cox-2 induction after treatment of ANA-1 mouse macrophages with IFN-γ. Numbers below each blot represent the GAPDH-adjusted density of each band, with the control (0 hour, no treatment) being a baseline of 1.0. The observation that for both markers (iNOS and Cox-2) density is lower in unstimulated cells exposed to Cl-amidine (0 hour, +10 µg/ml Cl-amidine, 5th lane) suggests Cl-amidine inhibits basal activity of macrophages. Accordingly, it also inhibits the activation of macrophages. (B) An oxidative burst in ANA-1 mouse macrophages is attenuated by pretreatment with Cl-amidine (10 µg/ml). Chemiluminescence was measured as described in Materials and Methods. Results were compared with no Cl-amidine control (± S.E.). (C) In the presence of an oxidative burst, target epithelial cells (HCT116 colon cancer cells) pretreated with 10 µg/ml Cl-amidine are protected from DNA damage. Results are represented as the mean Comet tail moment ± S.E., scoring 50 comets/treatment group. Representative images of Comets in each treatment group are shown above each bar graph. *Significant difference from the untreated (No Cl-amidine) macrophages that were cocultured for 4 hours (P < 0.01).

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Cl-amidine induces antioxidant enzymes (catalase, GPx1, SOD1) in IFN-γ–stimulated ANA-1 mouse macrophages and in vivo. (A) ANA-1 mouse macrophage cells were pretreated with 0–10 µg/ml Cl-amidine for 12 hours and then cells were stimulated with IFN-γ for 8 hours. Antioxidant enzymes of interest were suppressed in activated cells pretreated with 10 µg/ml (lane 4). (B–D) Mice from each of the indicated groups were euthanized on day 14, and colons were harvested from each animal and stained with catalase (B), GPx1 (C), and SOD1 (D) as described in Materials and Methods. Immunoreactivity scores (IRS) are shown for each group. Values represent the mean ± S.E. Significance is compared with the AOM + DSS only group: *P < 0.05; **P < 0.01; ***P < 0.005. Representative sections of each group were taken at 400× magnification, and positive staining is brown colored.

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    Cl-amidine attenuates the activation of white blood cells and protects from DNA damage in target epithelial cells in vivo. Mice were injected with AOM (10 mg/kg), then 1 week later they were given either water ad libitum or 2% DSS in the drinking water for 14 days as described in Materials and Methods and in Fig. 2. (A) Protein lysates from scraped mucosa of the colon (4 mice per group; lysates were combined) were examined for iNOS and GAPDH (internal control). Mice consuming 2% DSS had activation of only iNOS in both CD45+ and CD45− cells. Mice consuming Cl-amidine + 2% DSS had iNOS attenuated in both cell types. (B) After column separation of inflammatory cells from mucosal cells, we examined an oxidative burst of CD45+ inflammatory cells (4 mice per group). Mice consuming Cl-amidine + DSS exhibit CD45+ inflammatory cells with attenuated activity compared with mice on 2% DSS only. Chemiluminescence was measured as described in Materials and Methods and expressed as mean (± S.E.) relative light units (RLU) per 1 × 106 cells. *Significant difference from the AOM + DSS–only group (P < 0.05). (C) Mucosal epithelial cells were examined for DNA damage by Comet analysis. Results are presented as the mean (± S.E.) tail moment from 200 Comets taken from 4 mice per group. *Significant difference from the AOM + DSS–only group (P < 0.01). Representative Comets for each group are shown.

PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 353 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 353, Issue 1
1 Apr 2015
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Inhibiting Protein Arginine Deiminases Has Antioxidant Consequences
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
Citation Tools
Research ArticleGastrointestinal, Hepatic, Pulmonary, and Renal

Antioxidant/Anti-DNA Damage Consequences of PAD Inhibition

Erin E. Witalison, Xiangli Cui, Anne B. Hofseth, Venkataraman Subramanian, Corey P. Causey, Paul R. Thompson and Lorne J. Hofseth
Journal of Pharmacology and Experimental Therapeutics April 1, 2015, 353 (1) 64-70; DOI: https://doi.org/10.1124/jpet.115.222745

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleGastrointestinal, Hepatic, Pulmonary, and Renal

Antioxidant/Anti-DNA Damage Consequences of PAD Inhibition

Erin E. Witalison, Xiangli Cui, Anne B. Hofseth, Venkataraman Subramanian, Corey P. Causey, Paul R. Thompson and Lorne J. Hofseth
Journal of Pharmacology and Experimental Therapeutics April 1, 2015, 353 (1) 64-70; DOI: https://doi.org/10.1124/jpet.115.222745
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • ATP via P2X2/3 Facilitates ACh Release in the Human Bladder
  • DMOG, a prolyl hydroxylase inhibitor, increases hemoglobin levels without exacerbating hypertension and renal injury in salt-sensitive hypertensive rats.
  • Liver-Specific PHD Inhibitor
Show more Gastrointestinal, Hepatic, Pulmonary, and Renal

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2019 by the American Society for Pharmacology and Experimental Therapeutics